Health Condition 1: G409- Epilepsy, unspecified
Conditions
Interventions
Intervention1: Levetiracetam: Patients in the Levetiracetam group received oral Levetiracetam at a dose of 15ââ?¬â??30 mg/kg per
day twice daily at the onset of fever (T 37.5�°C) for 1 week (thera
Sponsors
Dr Rajkumar Surya
Eligibility
Inclusion criteria
Inclusion criteria: Children more than 1 month till 59 months, with history of two or more episodes of febrile seizures within the last 6 months
Exclusion criteria
Exclusion criteria: Episodes of previous seizures without fever, no Intracranial infections, no Head trauma, no structural or developmental anomalies of CNS, no history of intoxication and electrolyte disturbances, no congenital metabolic disease or chronic disease for which AED have to be prescribed for longer duration. All children on current use of anti-epileptic drugs, those parents who refuse consent or residing at distance of more than 30 km from hospital, and cannot come for follow -up will also be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effectiveness of oral intermittent levetiracetam vs clobazam in controlling seizure frequency associated with febrile events and febrile seizure recurrence rateTimepoint: 48 weeks follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| The primary variable in efficacy is seizure frequency associated with febrile events and FS recurrence rate (RR) during the 48-week follow-up. ââ?¬Â¢ The second variable in efficacy will be the side effects associated with the drugs.Timepoint: 48 weeks follow up | — |
Countries
India
Contacts
Public ContactDr Mangla Sood
IGMC Shimla
Outcome results
None listed